Aim: To explore the anti-inflammatory effects of a novel peptide designed to bind with the NF-кB p50 subunit. Methods: The affinity of the peptide binding with p50 was measured with a biosensor. Levels of tumor necrosis factor-α (TNF-a) and interleukin 6 (IL-6) from a human acute monocytic leukemia cell line (THP-1) treated with lipopolysaccharide (LPS) were measured using the ELISA method. In vivo anti-inflammatory effects of the peptide were tested with phorbol myristate acetate (PMA)-induced ear edema and zymosan A-induced peritonitis in mice. Results: The peptide has the ability to interact with the NF-кB p50 subunit and can effectively inhibit TNF-α and IL-6 production in the THP-1 cell line, PMA-induced ear edema and zymosan A-induced peritonitis in mice. Conclusion: The peptide may have therapeutic potential for the treatment of local acute inflammation.